Literature DB >> 10218738

Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension.

A Surdacki1, M Nowicki, J Sandmann, D Tsikas, R H Boeger, S M Bode-Boeger, O Kruszelnicka-Kwiatkowska, F Kokot, J S Dubiel, J C Froelich.   

Abstract

Our aim was to investigate systemic nitric oxide (NO) production and its potential determinants such as insulin resistance, dyslipidemia, and circulating methylated analogs of L-arginine in uncomplicated essential hypertension (EH). Nineteen newly diagnosed, untreated male subjects with mild pure uncomplicated EH and 11 normotensive controls were studied at rest after an overnight fast. The groups had comparable age, body mass index, creatinine clearance, cholesterol, fasting glucose, and insulin. In hypertensives, the urinary excretion rate of nitrite plus nitrate (Unox), an index of endogenous NO production, was depressed (56+/-17 vs. 77+/-23 micromol/mmol creatinine; p < 0.05), whereas plasma levels of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of NO synthesis, were increased (2.4+/-1.1 vs. 1.1+/-0.7 microM; p < 0.005). Circulating concentrations of symmetric dimethylarginine were similar in both groups (1.4+/-1.3 vs. 1.5+/-1.1 microM; p = NS). The L-arginine-to-ADMA ratio was reduced in hypertension (3.3+/-0.5 vs. 4.5+/-0.8; p < 0.001 for In-transformed data). There was no correlation between Unox and either the magnitude of insulin resistance or dyslipidemia in EH. Thus in male subjects with EH, endogenous systemic NO formation appears depressed, which is unrelated to accompanying insulin resistance or dyslipidemia. Circulating ADMA levels are increased in uncomplicated EH, which may be of potential relevance.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10218738     DOI: 10.1097/00005344-199904000-00020

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  82 in total

Review 1.  The nitric oxide pathway in the cardiovascular system.

Authors:  S Llorens; J Jordán; E Nava
Journal:  J Physiol Biochem       Date:  2002-09       Impact factor: 4.158

Review 2.  Age-related endothelial dysfunction : potential implications for pharmacotherapy.

Authors:  Rachel L Matz; Ramaroson Andriantsitohaina
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

3.  Effect of fenofibrate on LDL-induced endothelial dysfunction in rats.

Authors:  Tian-Lun Yang; Mei-Fang Chen; Bai-Ling Luo; Jing Yu; Jun-Lin Jiang; Yuan-Jian Li
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-08-14       Impact factor: 3.000

4.  Role of cardiovascular imaging in systemic autoimmune diseases.

Authors:  Simona Sitia; Luigi Gianturco; Livio Tomasoni; Maurizio Turiel
Journal:  World J Cardiol       Date:  2010-08-26

5.  Simultaneous bioanalysis of L-arginine, L-citrulline, and dimethylarginines by LC-MS/MS.

Authors:  Soyoung Shin; Sun-Mi Fung; Srinidi Mohan; Ho-Leung Fung
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2011-01-14       Impact factor: 3.205

6.  Dimethylarginine dimethylaminohydrolase-1 is the critical enzyme for degrading the cardiovascular risk factor asymmetrical dimethylarginine.

Authors:  Xinli Hu; Dorothee Atzler; Xin Xu; Ping Zhang; Haipeng Guo; Zhongbing Lu; John Fassett; Edzard Schwedhelm; Rainer H Böger; Robert J Bache; Yingjie Chen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-04-14       Impact factor: 8.311

Review 7.  [Asymmetric dimethylarginine (ADMA): A cardiovascular risk factor].

Authors:  Friedrich Mittermayer; Katarzyna Krzyzanowska; Michael Wolzt
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

8.  Unchanged asymmetric dimethylarginine levels in non-diabetic, premenopausal obese women who have common risk factors for cardiovascular disease.

Authors:  P Cetinalp-Demircan; A Can; Selda Bekpinar; Y Unlucerci; Y Orhan
Journal:  Endocrine       Date:  2007-04       Impact factor: 3.633

9.  Asymmetric and symmetric dimethylarginine concentration as an indicator of cardiovascular diseases in rheumatoid arthritis patients: a systematic review and meta-analysis of case-control studies.

Authors:  Parisa Zafari; Ahmadreza Zarifian; Reza Alizadeh-Navaei; Mahdi Taghadosi; Alireza Rafiei; Zahra Samimi; Fatemeh Niksolat
Journal:  Clin Rheumatol       Date:  2019-08-03       Impact factor: 2.980

10.  Asymmetric dimethylarginine in angiotensin II-induced hypertension.

Authors:  Jennifer M Sasser; Natasha C Moningka; Mark W Cunningham; Byron Croker; Chris Baylis
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-12-16       Impact factor: 3.619

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.